<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031846</url>
  </required_header>
  <id_info>
    <org_study_id>V114-025</org_study_id>
    <secondary_id>2018-003787-31</secondary_id>
    <secondary_id>V114-025</secondary_id>
    <nct_id>NCT04031846</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)</brief_title>
  <acronym>PNEU-PED-EU-1</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Active-comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (PNEU-PED-EU-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability and immunogenicity of V114 when
      administered to 2-month old infants. The primary hypotheses are: 1) V114 is non-inferior to
      Prevenar 13™ for the 13 shared serotypes between V114 and Prevenar 13™ based on response
      rates at 30 days post toddler dose (PTD); 2) V114 is superior to Prevenar 13™ for the 2
      serotypes unique to V114 based on the response rates at 30 days PTD; 3) V114 is non-inferior
      to Prevenar 13™ for the 13 shared serotypes between V114 and Prevenar 13™ based on
      anti-pneumococcal polysaccharide (PnPs) serotype-specific Immunoglobin G (IgG) geometric mean
      concentrations (GMCs) at 30 days PTD; and 4) V114 is superior to Prevenar 13™ for the 2
      serotypes unique to V114 based on anti-PnPs serotype-specific IgG GMCs at 30 days PTD.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 4, 2019</start_date>
  <completion_date type="Anticipated">October 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 19, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants That Report at Least 1 Solicited Injection-site Adverse Event (AE)s</measure>
    <time_frame>Up to 14 days post any V114 vaccination</time_frame>
    <description>Injection-site AEs solicited on the Vaccine Report Card were redness, swelling, hard lump, and pain/tenderness. The percentage of participants with 1 or more solicited injection-site AEs will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants that Report at Least 1 Solicited Systemic AE</measure>
    <time_frame>Up to 14 days post any V114 vaccination</time_frame>
    <description>Systemic AEs solicited on the Vaccine Report Card were irritability, drowsiness, hive/welts, and appetite loss. The percentage of participants with 1 or more solicited systemic AEs will be assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants That Report at Least 1 Vaccine-related Serious Adverse Event (SAE)</measure>
    <time_frame>Day 1 up to 6 months post last V114 vaccination</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. A serious adverse event (SAE) is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a cancer, is an overdose, or is another important medical event. The percentage of participants that experienced 1 or more SAEs that was reported as at least possibly related to the study drug will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-pneumococcal Polysaccharide (PnPs) Serotype-specific IgG Geometric Mean Concentrations (GMC) for Each Serotype at 30 Days Post Toddler Dose (PTD)</measure>
    <time_frame>30 days PTD (Postdose 3 for full-term infants; Postdose 4 for preterm infants)</time_frame>
    <description>Sera from participants will be used to measure vaccine-induced anti-PnPs serotype-specific IgG for all the 15 serotypes using pneumococcal electrochemiluminescence (PnECL). The GMC for each serotype contained in V114 will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Meet Serotype-specific Immunoglobin G (IgG) Threshold Value of ≥0.35 μg/mL) for Each Serotype Contained in V114: 30 Days Post Toddler Dose (PTD)</measure>
    <time_frame>30 days PTD (Postdose 3 for full-term infants; Postdose 4 for preterm infants)</time_frame>
    <description>Sera from participants will be used to measure vaccine-induced anti-PnPs serotype-specific IgG for all the 15 serotypes using pneumococcal electrochemiluminescence (PnECL). The percentage that achieve the threshold value of ≥0.35 μg/mL will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Meet Antigen-Specific Threshold Value for Each Antigen in Infanrix™ Hexa: 30 Days PTD</measure>
    <time_frame>30 days PTD (Postdose 3 for full-term infants; Postdose 4 for preterm infants)</time_frame>
    <description>Sera from participants will be used to measure vaccine-induced antibodies for the antigens contained in Infanrix. The percentage that achieve the antigen-specific threshold value will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-rotavirus Immunoglobulin A (IgA) Geometric Mean Titers (GMTs) of Rotarix™: 30 Days Post Primary Series (PPS)</measure>
    <time_frame>30 days PPS (Postdose 2 for fullterm infants; Postdose 3 for preterm infants)</time_frame>
    <description>Sera from participants will be used to measure vaccine-induced antibodies (Immunoglobin A; [IgA]) for the antigens contained in Rotarix™. The GMT for each antigen contained in Rotarix™ will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PnPs Serotype-specific IgG Geometric Mean Concentrations (GMCs) for Each Serotype Contained in V114: 30 Days Post Primary Series (PPS)</measure>
    <time_frame>30 days PPS; (Postdose 2 for full-term infants; Postdose 3 for preterm infants)</time_frame>
    <description>Sera from participants will be used to measure vaccine-induced anti-PnPs serotype-specific IgG for all the 15 serotypes using PnECL. The GMC for each serotype contained in V114 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Meet Serotype-specific Immunoglobin G (IgG) Threshold Value of ≥0.35 μg/mL for Each Serotype Contained in V114; 30 Days PPS</measure>
    <time_frame>30 days PPS (Postdose 2 for full-term infants; Postdose 3 for preterm infants)</time_frame>
    <description>Sera from participants will be used to measure vaccine-induced anti-PnPs serotype-specific IgG for all the 15 serotypes using PnECL. The percentage that achieve the threshold value of ≥0.35 μg/mL will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PnPs Serotype-specific Opsonophagocytic Activity (OPA) GMTs of Each Serotype Contained in V114: 30 Days PTD</measure>
    <time_frame>30 days PTD (Postdose 3 for full-term infants; Postdose 4 for preterm infants)</time_frame>
    <description>Sera from participants will be used to measure vaccine-induced anti-PnPs serotype-specific OPA for all the 15 serotypes contained in V114. The OPA GMT for each serotype will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Meet Serotype-specific OPA Threshold Value for Each Serotype Contained in V114: 30 Days PTD</measure>
    <time_frame>30 days PTD (Postdose 3 for full-term infants; Postdose 4 for preterm infants)</time_frame>
    <description>Sera from participants will be used to measure vaccine-induced anti-PnPs serotype-specific OPA for the antigens contained in V114. The percentage that achieve the GMT response threshold value will be assessed for each serotype.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1180</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Full-term infants received a 0.5 mL intramuscular injection of V114 at approximately 2, 4, and 11-15 months of age (Study Day 1, Month 2, and Month 9-13). Preterm infants received a 0.5 mL intramuscular injection of V114 at approximately 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13). All infants also received intramuscular injection of 0.5 mL Infanrix™ hexa at approximately 2, 3, 4, and 11-15 months of age and 1.5 mL oral dose of Rotarix™ at 2 and 4 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevenar 13™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Full-term infants received a 0.5 mL intramuscular injection of Prevenar 13™ at approximately 2, 4, and 11-15 months of age (Study Day 1, Month 2, and Month 9-13). Preterm infants received a 0.5 mL intramuscular injection of Prevenar 13™ at approximately 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13). All infants also received intramuscular injection of 0.5 mL Infanrix™ hexa at approximately 2, 3, 4, and 11-15 months of age and 1.5 mL oral dose of Rotarix™ at 2 and 4 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rotarix™</intervention_name>
    <description>Single 1.5 mL oral dose at 2 and 4 months of age (Study Day 1 and Month 2)</description>
    <arm_group_label>Prevenar 13™</arm_group_label>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infanrix™ hexa</intervention_name>
    <description>Single 0.5 mL intramuscular injection at 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13)</description>
    <arm_group_label>Prevenar 13™</arm_group_label>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V114</intervention_name>
    <description>15-valent pneumococcal conjugate vaccine (PCV) containing 13 serotypes present in Prevenar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration,</description>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevenar 13™</intervention_name>
    <description>13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL intramuscular administration.</description>
    <arm_group_label>Prevenar 13™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Healthy

          -  Has a legally acceptable representative who understands the study procedures,
             alternate treatments available, and risks involved with the study and voluntarily
             agrees to participate by giving written informed consent

        Exclusion Criteria

          -  History of invasive pneumococcal disease [(IPD); positive blood culture, positive
             cerebrospinal fluid culture, or other sterile site] or known history of other culture
             positive pneumococcal disease

          -  Has a known or suspected impairment of immunological function

          -  Has a history of congenital or acquired immunodeficiency

          -  Has, or his/her mother has, a documented human immunodeficiency virus (HIV) infection

          -  Has, or his/her mother has, a documented hepatitis B surface antigen - positive test

          -  Has known or history of functional or anatomic asplenia

          -  Has failure to thrive based on the clinical judgement of the Investigator

          -  Has a bleeding disorder contraindicating intramuscular vaccination

          -  Has a history of autoimmune disease (including but not limited to systemic lupus
             erythematosus, antiphospholipid syndrome, Behcet's disease, autoimmune thyroid
             disease, polymyositis and dermatomyositis, scleroderma, Type 1 diabetes mellitus, or
             other autoimmune disorders)

          -  Has a known neurologic or cognitive behavioral disorder, including
             encephalitis/myelitis, acute disseminating encephalomyelitis, pervasive development
             disorder, and related disorders

          -  Has received a dose of any pneumococcal vaccine prior to study entry

          -  Has received &gt;1 dose of monovalent hepatitis B vaccine or hepatitis B-based
             combination vaccine prior to study entry

          -  Has received a dose of any acellular pertussis- or whole cell pertussis-based
             combination vaccines, Haemophilus influenzae type b conjugate vaccine, poliovirus
             vaccine, rotavirus vaccine, or any other combination thereof, prior to study entry

          -  Has received a blood transfusion or blood products, including immunoglobulins

          -  Has participated in another clinical study of an investigational product before the
             beginning or anytime during the duration of the current clinical study. Participants
             enrolled in observational studies may be included; these will be reviewed on a
             case-by-case basis for approval by the Sponsor

          -  Is or has an immediate family member (eg, parent/legal guardian or sibling) who is
             investigational site or Sponsor staff directly involved with this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queensland Children s Hospital ( Site 0004)</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaccine and Immunisation Research Group - VIRGo ( Site 0002)</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Telethon Kids Institute ( Site 0003)</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O.L.V. Ziekenhuis Aalst ( Site 0144)</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint Jan Brugge-Oostende ( Site 0147)</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares Gent ( Site 0142)</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent ( Site 0141)</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Henry Serruys ( Site 0148)</name>
      <address>
        <city>Oostende</city>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Delta ( Site 0143)</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr. Daniel Drazan - Prakticky lekar pro deti a dorost ( Site 0151)</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>377 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MU Dr. Jan Nemecek - Prakticky lekar pro deti a dorost ( Site 0152)</name>
      <address>
        <city>Melnik</city>
        <zip>276 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr. Josef Zemanek ( Site 0153)</name>
      <address>
        <city>Tynec nad Sazavou</city>
        <zip>257 41</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vee Perearstikeskus ( Site 0163)</name>
      <address>
        <city>Paide</city>
        <state>Jarvamaa</state>
        <zip>72713</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merekivi Perearstid ( Site 0165)</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merelahe Perearstikeskus OU ( Site 0164)</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinu Arst Tervisekeskus ( Site 0167)</name>
      <address>
        <city>Tallinn</city>
        <zip>11313</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosenthali Perearstikeskus OU ( Site 0166)</name>
      <address>
        <city>Tallinn</city>
        <zip>11315</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliiniliste Uuringute Keskus OU ( Site 0161)</name>
      <address>
        <city>Tartu</city>
        <zip>50160</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NETSTAP - Sandner ( Site 0072)</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderarztpraxis ( Site 0061)</name>
      <address>
        <city>Bramsche</city>
        <zip>49565</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Schmute ( Site 0078)</name>
      <address>
        <city>Datteln</city>
        <zip>45711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis fur Kinder und Jugendmedizin Eivy Franke Beckmann ( Site 0064)</name>
      <address>
        <city>Erfurt</city>
        <zip>99086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderarztpraxis Dr. Friedrich Kaiser &amp; Dr. Marinesse ( Site 0065)</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderarztpraxis Dr. Juenger ( Site 0073)</name>
      <address>
        <city>Herxheim</city>
        <zip>76863</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderpraxis Dr. med. Andreas Petri ( Site 0066)</name>
      <address>
        <city>Huerth</city>
        <zip>50354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderarztpraxis ( Site 0068)</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>41236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinder- und Jugendaerztliche Gemeinschaftspraxis ( Site 0077)</name>
      <address>
        <city>Oberhausen</city>
        <zip>46145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxiszentrum Triftplatz ( Site 0075)</name>
      <address>
        <city>Schoenau</city>
        <zip>83471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Siegfried Simmet ( Site 0069)</name>
      <address>
        <city>Schweigen</city>
        <zip>76889</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderarztpraxis Dr. Rolf Ebert &amp; Dr. Matthias Huebener ( Site 0062)</name>
      <address>
        <city>Tauberbischofsheim</city>
        <zip>97941</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderaerztliche Gemeinschaftspraxis Drs. Westerholt/Matyas ( Site 0074)</name>
      <address>
        <city>Wolfsburg</city>
        <zip>38448</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderarztpraxis ( Site 0063)</name>
      <address>
        <city>Wuerselen</city>
        <zip>52146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pan and Aglaia Kyriakou Children s Hospital ( Site 0183)</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Athens - Aghia Sophia Childrens Hospital ( Site 0185)</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Attikon University General Hospital of Athens ( Site 0182)</name>
      <address>
        <city>Athens</city>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larissa ( Site 0184)</name>
      <address>
        <city>Larissa</city>
        <zip>411 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hippokration General Hospital of Thessaloniki ( Site 0181)</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 42</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Bydgoszcz ( Site 0086)</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatny Gabinet Lekarski Dr med Jerzy Brzostek ( Site 0084)</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pawla II ( Site 0085)</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gravita Diagnostyka i Leczenie Nieplodnosci ( Site 0092)</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym ( Site 0091)</name>
      <address>
        <city>Lomianki</city>
        <zip>05-092</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Szpital Dzieciecy Poznan ( Site 0089)</name>
      <address>
        <city>Poznan</city>
        <zip>61-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZ Lecznictwa Ambulatoryjnego - Michalkowice - Jarosz i Partnerzy ( Site 0087)</name>
      <address>
        <city>Siemianowice Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital im. sw. Jadwigi Slaskiej w Trzebnicy ( Site 0083)</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny ( Site 0093)</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAI Childrens City Clinical Hospital 11 ( Site 0047)</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of Russian Academy Science ( Site 0052)</name>
      <address>
        <city>Moscow</city>
        <zip>119333</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children s City Polyclinic No. 45 of the Nevsky District ( Site 0048)</name>
      <address>
        <city>St.Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol ( Site 0102)</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Antequera ( Site 0111)</name>
      <address>
        <city>Antequera</city>
        <state>Malaga</state>
        <zip>29200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Paiporta ( Site 0117)</name>
      <address>
        <city>Paiporta</city>
        <state>Valencia</state>
        <zip>46200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Quart de Poblet ( Site 0115)</name>
      <address>
        <city>Quart de Poblet</city>
        <state>Valencia</state>
        <zip>46930</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario 12 de Octubre ( Site 0106)</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 0107)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sanitas La Moraleja ( Site 0103)</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago ( Site 0109)</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Estudios e Investigacion IHP ( Site 0101)</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Serreria II ( Site 0116)</name>
      <address>
        <city>Valencia</city>
        <zip>46022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Eliana ( Site 0114)</name>
      <address>
        <city>Valencia</city>
        <zip>46183</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

